ISKJ | Fundamental Growth +30%
Updated
0. Top Russian Medical Genetic company
1. Develop alternative to Sputnik COVID-19 vacine named Betuvax-CoV-2
2. Russian Health Ministry approves clinical trails of Betuvax at September 27 2021. Clinical trails involve 116 volonteer without chronic diseases
3. Forecast release date midwinter 2021.
4. In case of anual vaccination of 1% Russian population target price: 120 RUB
5. In case of anu vaccination rate of 4%, target: 320 RUB
6. Govermental support rate up to +10-20% price impact
7. Lot's of other medical projects that support ISKJ fundamental price at 85 RUB without Betuvax project impact.
Target price: 125 RUB
1. Develop alternative to Sputnik COVID-19 vacine named Betuvax-CoV-2
2. Russian Health Ministry approves clinical trails of Betuvax at September 27 2021. Clinical trails involve 116 volonteer without chronic diseases
3. Forecast release date midwinter 2021.
4. In case of anual vaccination of 1% Russian population target price: 120 RUB
5. In case of anu vaccination rate of 4%, target: 320 RUB
6. Govermental support rate up to +10-20% price impact
7. Lot's of other medical projects that support ISKJ fundamental price at 85 RUB without Betuvax project impact.
Target price: 125 RUB
Trade active
Upside: 185 RUBSupply of Neovaskogulen product to the USA market
Trade closed: target reached
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.